Behind the Scenes of DexCom's Latest Options Trends
Behind the Scenes of DexCom's Latest Options Trends
Whales with a lot of money to spend have taken a noticeably bearish stance on DexCom.
擁有大量資金的鯨魚們對德康醫療採取了明顯的看淡態度。
Looking at options history for DexCom (NASDAQ:DXCM) we detected 17 trades.
查看德康醫療 (納斯達克:DXCM) 的期權交易歷史，我們發現了17筆交易。
If we consider the specifics of each trade, it is accurate to state that 41% of the investors opened trades with bullish expectations and 47% with bearish.
如果我們考慮每筆交易的具體情況，可以準確地說，41%的投資者以牛市預期開倉，47%的投資者以熊市預期開倉。
From the overall spotted trades, 9 are puts, for a total amount of $680,373 and 8, calls, for a total amount of $608,895.
從所有發現的交易數據來看，買入看跌期權的交易有9筆，金額總計爲$680,373，買入看漲期權的交易有8筆，金額總計爲$608,895。
Expected Price Movements
預期價格波動
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $45.0 to $110.0 for DexCom over the recent three months.
根據交易活動情況，似乎重要的投資者們目標價區間爲$45.0到$110.0區間內的德康醫療股票，在最近三個月內。
Analyzing Volume & Open Interest
分析成交量和未平倉合約
In terms of liquidity and interest, the mean open interest for DexCom options trades today is 694.29 with a total volume of 2,476.00.
在流動性和興趣方面，德康醫療期權交易的平均未平倉合約數爲694.29，總成交量爲2,476.00。
In the following chart, we are able to follow the development of volume and open interest of call and put options for DexCom's big money trades within a strike price range of $45.0 to $110.0 over the last 30 days.
在下述圖表中，我們能夠跟蹤過去30天$45.0至$110.0跨行權價德康醫療大手交易的認購和認沽期權成交量和未平倉合約的發展情況。
DexCom Option Volume And Open Interest Over Last 30 Days
德康醫療過去30天期權成交量和未平倉合約情況
Biggest Options Spotted:
最大的期權交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DXCM | PUT | SWEEP | BULLISH | 06/20/25 | $12.2 | $11.8 | $12.2 | $70.00 | $245.2K | 32 | 201 |
| DXCM | PUT | TRADE | BEARISH | 06/20/25 | $2.8 | $1.8 | $2.7 | $45.00 | $189.0K | 63 | 700 |
| DXCM | CALL | TRADE | BEARISH | 09/20/24 | $19.5 | $16.6 | $17.5 | $50.00 | $105.0K | 7 | 120 |
| DXCM | CALL | SWEEP | BEARISH | 01/17/25 | $10.3 | $10.0 | $10.0 | $65.00 | $100.0K | 1.0K | 40 |
| DXCM | CALL | TRADE | BULLISH | 09/20/24 | $17.8 | $13.1 | $16.0 | $50.00 | $96.0K | 7 | 0 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DXCM | 看跌 | SWEEP | 看好 | 06/20/25 | $12.2 | $11.8 | $12.2 | 70.00美元 | $245.2K | 32 | 201 |
| DXCM | 看跌 | 交易 | 看淡 | 06/20/25 | $2.8 | $1.8 | $2.7 | $45.00 | $189.0K | 63 | 700 |
| DXCM | 看漲 | 交易 | 看淡 | 09/20/24 | $19.5。 | $16.6 | $17.5 | $50.00 | $105.0K | 7 | 120 |
| DXCM | 看漲 | SWEEP | 看淡 | 01/17/25 | $10.3 | $10.0 | $10.0 | $65.00 | $100.0K | 1.0K | 40 |
| DXCM | 看漲 | 交易 | 看好 | 09/20/24 | $17.8 | $13.1 | $16.0 | $50.00 | $96.0K | 7 | 0 |
About DexCom
關於德康醫療
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
德康醫療設計和商業化連續血糖監測系統，用於糖尿病患者。CGM系統是替代傳統血糖儀過程的一種方法，該公司正在發展其CGM系統，以提供與銀休特和Tandem的胰島素泵集成，實現自動胰島素輸送。
Present Market Standing of DexCom
德康醫療目前的市場地位
- Trading volume stands at 6,824,913, with DXCM's price up by 7.0%, positioned at $68.48.
- RSI indicators show the stock to be may be oversold.
- Earnings announcement expected in 87 days.
- 交易量爲6,824,913，DXCM的價格上漲了7.0%，位於$68.48。
- RSI指標顯示該股票可能已被超賣。
- 預計將在87天內宣佈收益。
What Analysts Are Saying About DexCom
分析師們對德康醫療的看法
In the last month, 5 experts released ratings on this stock with an average target price of $104.0.
在過去的一個月中，有5位專家發佈了對這隻股票的評分，平均目標價格爲$104.0。
- An analyst from Canaccord Genuity has decided to maintain their Buy rating on DexCom, which currently sits at a price target of $145.
- Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on DexCom with a target price of $120.
- In a cautious move, an analyst from JP Morgan downgraded its rating to Neutral, setting a price target of $75.
- An analyst from Stifel persists with their Buy rating on DexCom, maintaining a target price of $90.
- An analyst from Piper Sandler persists with their Overweight rating on DexCom, maintaining a target price of $90.
- Canaccord Genuity的一位分析師決定維持他們對德康醫療的買入評級，目前的價格目標爲$145。
- 大摩資源lof的一位分析師持續維持對德康醫療的中立評級，目標價爲$120。
- 小心謹慎地，JP摩根下調其評級至中立，設定價格目標爲$75。
- Stifel的一名分析師堅持對德康醫療買入評級，目標價保持在90美元。
- 派傑投資的一位分析師堅持對德康醫療超配評級，目標價保持在90美元。
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
期權與僅交易股票相比是一種更具風險的資產，但它們具有更高的利潤潛力。認真的期權交易者通過每日學習，進出交易，跟隨多個指標並密切關注市場來管理這種風險。